Repatha Pricing Pressure Might Actually Increase After Outcomes Trial
Executive Summary
Amgen's FOURIER study prompts ICER to plan new value-based price benchmark for Repatha below its previously recommended range of $5,404 to $7,735 per year.
You may also be interested in...
Praluent Pricing: Collaboration With ICER Sets A New Standard
Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.
ICER And The VA: Match Made in Heaven?
Institute for Clinical and Economic Review partners with the US Department of Veterans Affairs to support the agency's approach to negotiating and contracting for prescription drugs.
Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund
Harvard Pilgrim Chief Medical Officer Michael Sherman said the full warranty behind the agreement is the right kind of deal to balance access and cost.